Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997189 · ClinicalTrials.gov registry record · Phase 2
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
A Phase 2 study, sponsored by Otonomy.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02997189 is a Phase 2 study that was terminated before completion, run by Otonomy. The registered enrollment target is 12 participants.
The verdict
NCT02997189, a Phase 2 study, was terminated before completion, sponsored by Otonomy.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of cancer.
Interventions
- DRUG OTO-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2017-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02997189
The ClinicalTrials.gov registry entry for NCT02997189 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otonomy, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTO-104 is the first listed.
NCT02997189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02997189 about?
NCT02997189 is a clinical study titled "Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss". This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of cancer.
What is the current status of trial NCT02997189?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-11-15. Estimated completion is 2017-09-26.
What interventions are being tested in trial NCT02997189?
The interventions under investigation include: OTO-104 (DRUG).
Who is sponsoring clinical trial NCT02997189?
This trial is sponsored by Otonomy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.